A multibillion-dollar licensing alliance between Bristol Myers Squibb and Jiangsu Hengrui has triggered renewed U.S. political pressure on outbound investment rules for biotechnology. House Select Committee on the Chinese Communist Party chairman John Moolenaar sent a letter to Treasury Secretary Scott Bessent urging biotechnology be added as a prohibited technology under the COINS Act framework. The concern centers on what lawmakers describe as a “dangerous surge” of American capital and know-how into China’s biotech sector, following BMS’s plan to advance 13 early development programs through the Hengrui partnership across oncology, hematology, and immunology. The letter raises the possibility of tightening investment restrictions specifically targeting life-science capabilities, which could alter the deal landscape for cross-border licensing, funding, and co-development structures. For companies negotiating terms, the episode signals that compliance risk is rising not only from scientific and regulatory considerations but also from evolving geopolitical and national-security interpretations.